$36.00 – $3,094.00
Cas NO: 1445583-51-6
Appearance: white powder
Purity: Above 99.5%
ADB-FUBINACA POWDER is a designer drug identified in synthetic marijuana blends in Japan in 2013.  In 2018, it was the third-most common synthetic cannabinoid recognized in medicines confiscated by the Medication Enforcement Administration.
The (S)- enantiomer of ADB-FUBINACA is explained in a 2009 Pfizer patent  and has been reported to be a potent agonist of the CB1 receptor and also the CB2 receptor with EC50 values of 1.2 nM as well as 3.5 nM, specifically. ADB-FUBINACA includes a carboxamide team at the 3-indazole setting, like SDB-001 and STS-135. ADB-FUBINACA seems the product of rational medication design, because it differs from AB-FUBINACA only by the replacement of the isopropyl team with a tert-butyl team.
An analogue of ADB-FUBINACA, ADSB-FUB-187, consisting of an extra functionalized carboxamide substituent was lately reported.
One death through coronary arterial thrombosis has actually been linked to ADB-FUBINACA intoxication.
At least an additional 8 deaths in Hungary in 2015 are connected to the use of this product, all fatalities were children listed below 21.
Twenty-three ADB-FUBINACA major metabolites were recognized in a number of incubations with cryopreserved human hepatocytes. Significant metabolic paths were alkyl as well as indazole hydroxylation, incurable amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.
Crystal 5g, Crystal 25g, Crystal 50g, Crystal 100g, Crystal 250g, Crystal 500g, Crystal 1000g